ciclesonide (Alvesco) vs fluticasone propionate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
ciclesonide (Alvesco)
Marketed by Azurity Pharmaceuticals and partners
NCT00163397 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.
Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.
Reported efficacy
Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)
Result source: NCT00174720
fluticasone propionate
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | ciclesonide (Alvesco) | fluticasone propionate |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00174720 | 1.9 vs 2.1vs Fluticasone PropionateNCT004526991 other result
|
| Trough FEV1, change | —Not posted · NCT00174720 | 0.2 vs 0.1+0.2 vs placeboNCT0213964425 other results
|
| ACQ-5, change | —Not posted · NCT00174720 | —Not posted · NCT00158834 |
| OCS dose reduction | —Not posted · NCT00174720 | —Not posted · NCT00158834 |
Severe exacerbations, annualised rate
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone propionate
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
1 other result
- 2.6 vs 2.7 NCT00452348
Trough FEV1, change
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone propionate
- 0.2 vs 0.1+0.2 vs placeboNCT02139644
25 other results
- 0.2 vs 0.1 NCT02139644
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- -0.1 vs -0.1 NCT02094937
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01576718
- 0.3 vs 0.1 NCT01479621
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT00452348
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01563029
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01563029
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01576718
- 0.3 vs 0.1 NCT01563029
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone propionate
- —Not posted · NCT00158834
OCS dose reduction
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone propionate
- —Not posted · NCT00158834
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ciclesonide (Alvesco): 4 of 4 rows · fluticasone propionate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ciclesonide (Alvesco) | fluticasone propionate |
|---|---|---|
| Dropout rate | —a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result11.8% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy | —100/25 µg QDb NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results—50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 53.1%Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence 37.5%Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 25.5%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 2.8%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 28%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 27.5%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 20.3%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result5.1% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy | —100/25 µg QDb NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results—50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence —Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 1.9%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence —50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 1.7%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.8%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result0.8% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy | 1.4%100/25 µg QDb NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results0%50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence 0%Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 2.3%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence 2%50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence 0%100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 1.9%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence 0.8%100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence 0%50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 9.8%200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 6.4%200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5%100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.5%100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 0.6%100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 0.8%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.8%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0.9%100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0.9%50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0%400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 1.9%100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 1%50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a headaches/migraine 23.8% (placebo 22.7%) respiratory infections 19% (placebo 18.2%) bilateral otitis media 4.8% (placebo 0%) NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 | 100/25 µg QDb upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence show 29 more results250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence 250/50 mcg BID nasopharyngitis 17.4% headache 16.5% upper respiratory tract infection 14.5% NCT00452348 · Phase 4 · registry result, not featured evidence 50/100 mcg BD headache 18% nasopharyngitis 9.3% rhinitis 8% NCT00353873 · Phase 4 · registry result, not featured evidence 100/50mcg BID headache 3.2% upper respiratory tract infection 3.2% abdominal pain upper 2.4% NCT00118716 · Phase 4 · registry result, not featured evidence 50/12.5 mcg BID nasopharyngitis 4.3% (placebo 5.3%) NCT02980133 · Phase 3 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg headache 7% (placebo 3.9%) nasopharyngitis 7% (placebo 3.1%) upper respiratory tract infection 3.1% (placebo 4.7%) NCT02139644 · Phase 3 · registry result, not featured evidence 50 mcg nasopharyngitis 5.4% (placebo 3.1%) upper respiratory tract infection 5.4% (placebo 4.7%) headache 1.6% (placebo 3.9%) NCT02139644 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 200/12.5 mcg upper respiratory tract infection 18% sinusitis 10.5% nasopharyngitis 9% NCT02175771 · Phase 3 · registry result, not featured evidence 200 mcg upper respiratory tract infection 13.6% cough 10.4% nasopharyngitis 10.4% NCT02175771 · Phase 3 · registry result, not featured evidence 100/12.5 mcg upper respiratory tract infection 17.5% nasopharyngitis 12.5% cough 11.7% NCT02175771 · Phase 3 · registry result, not featured evidence 100 mcg upper respiratory tract infection 18.1% nasopharyngitis 13.4% sinusitis 11.8% NCT02175771 · Phase 3 · registry result, not featured evidence 100/50 HFA headache 15% nasopharyngitis 9.2% upper respiratory tract infection 6.4% NCT00441441 · Phase 3 · registry result, not featured evidence 100 µg OD cough 8.5% (placebo 5%) headache 5.9% (placebo 1.7%) rhinorrhoea 5.1% (placebo 1.7%) NCT01563029 · Phase 2 · registry result, not featured evidence 50 µg OD pharyngitis 5.8% (placebo 3.4%) bronchitis 3.3% (placebo 0.8%) nasopharyngitis 3.3% (placebo 3.4%) NCT01563029 · Phase 2 · registry result, not featured evidence 25 µg OD nasopharyngitis 7.6% (placebo 3.4%) cough 5.9% (placebo 5%) oropharyngeal pain 5.1% (placebo 0.8%) NCT01563029 · Phase 2 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100 mcg upper respiratory tract infection 4.9% (placebo 2.9%) nasopharyngitis 2.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 50 mcg nasopharyngitis 6.7% (placebo 4.8%) upper respiratory tract infection 2.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 25 mcg nasopharyngitis 4.8% (placebo 4.8%) upper respiratory tract infection 1.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 12.5 mcg upper respiratory tract infection 6.8% (placebo 2.9%) nasopharyngitis 3.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ciclesonide (Alvesco)
show 1 more result
fluticasone propionate
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 25 more results
show 12 more results
show 4 more results
show 6 more results
+ 32 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ciclesonide (Alvesco)'s landscape · fluticasone propionate's landscape